OANA VIOLA BADULESCU, DAN VINTILA, BOGDAN MIHNEA CIUNTU, MANUELA CIOCOIU, PAUL DAN SIRBUTHE ROLE OF COAGULATION FACTOR VIII SUBSTUTUTION THERAPY IN THE MANAGEMENT OF TYPE A HEMOPHILIA COMPLICATIONS Hemophilia is a pathologycharacterized by a disturbance in the normal clotting process of the blood, as a result of a functional deficit of clotting factor VIII or IX.There are two types of hemophilia: type A and type B, the former expressing a deficit of factor VIII, while the latter a deficit of factor IX.C.L., a 43 years old male, was diagnosed at the age of 8 months with a severe form of type A hemophilia. From that time, the patient presentedhemorrhagic episodes, resulting either from trauma or appearing spontaneously and requiring factor VIII substitution therapy and hemostatic treatment.Bloodwork show a prolonged aPTT, as well as microcytic anemia with a low iron serum level, as a result of chronic blood loss.The particularity of this case consists in the high degree of development and recurrence of hemophilia associated complications, leading to superior and inferior limb motor deficits and chronic pain which is currently managed with opioid medication. Also,the patient suffers from chronic hepatitis due to infection with B and C hepatitis viruses as a result of previous lifesaving plasma substitution therapy.Even though the clinical manifestations of hemophilia excert a high cost on the patient’s life as well as the medical system, timely prophylactic factor VIII substitution therapy from the moment of diagnosis until the age of 18 can reduce both the toll on the patient’s health and quality of life and also on the medical costs. Thus, we stress the fact that prophylactic therapy can have a beneficial effect both on patient’s life and also on the health system.